135 related articles for article (PubMed ID: 20471294)
1. Insights into designing the dual-targeted HER2/HSP90 inhibitors.
Chen CY; Chen CY
J Mol Graph Model; 2010 Aug; 29(1):21-31. PubMed ID: 20471294
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
Awale M; Mohan CG
J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
[TBL] [Abstract][Full Text] [Related]
3. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA.
Morshed MN; Muddassar M; Pasha FA; Cho SJ
Chem Biol Drug Des; 2009 Aug; 74(2):148-58. PubMed ID: 19563463
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
Saxena AK; Saxena S; Chaudhaery SS
SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
[TBL] [Abstract][Full Text] [Related]
9. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
10. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
12. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
13. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
15. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
17. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
18. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.
Qin J; Lei B; Xi L; Liu H; Yao X
Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]